CSF2 and breast cancer: In another phase II study, 42 BC patients were vaccinated with a multi-antigen vaccine, which included autologous and allogeneic breast cancer cells, three TAAs (CA15-3, CEA, and CA125), and low doses of GM-CSF and IL-2.